COMPARATIVE IN-VITRO ACTIVITY OF PIPERACILLIN TAZOBACTAM AGAINST RECENT CLINICAL ISOLATES, A DUTCH NATIONAL MULTICENTER STUDY

被引:6
|
作者
STOBBERINGH, EE
MACLAREN, DM
SCHMITZ, PIM
DIRKSGO, SIS
DANKERT, J
LIGTVOET, EEJ
LICHTENDAHLBERNARDS, AT
HORREVORTS, AM
THEWESSEN, EAPM
BANFFER, JRJ
WAGENVOORT, JHT
HENDRIKS, WDH
BRIMICOMBE, RW
LIM, BT
VISSER, MR
VANKLINGEREN, B
VANKREGTEN, E
DEJONG, J
SCHREUDER, H
SABBE, LJM
WINTERMANS, RGF
DIEPERSLOOT, RJA
SONDERKAMP, HJA
VANDIJKE, BF
FABIUS, GTJ
DAVIES, BI
HOOGKAMPKORSTANJE, JAA
DEJONG, A
SEVERIN, WPJ
DEGENER, JE
MANSON, WL
VERBRUGH, H
机构
[1] FREE UNIV AMSTERDAM HOSP,DEPT CLIN MICROBIOL & INFECT CONTROL,AMSTERDAM,NETHERLANDS
[2] DR DANIEL DEN HOED CANC CTR,DEPT TRIALS & STAT,3008 AE ROTTERDAM,NETHERLANDS
关键词
D O I
10.1093/jac/34.5.777
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In this Dutch national survey piperacillin-tazobactam had a MIC(90) of less than or equal to 8 mg/L for Enterobacteriaceae (Enterobacter cloacae excluded) and Pseudomonas aeruginosa, 64 mg/L for E. cloacae, and 4 mg/L for Acinetobacter spp. The corresponding MIC(90) values for piperacillin alone were less than or equal to 256 mg/L, 256 mg/L, 16 mg/L and 32 mg/L. Only 15 of 93 piperacillin-tazobactam resistant E. cloacae strains were sensitive for ceftazidime, whereas 41 of 93 ceftazidime-resistant E. cloacae were sensitive to piperacillin-tazobactam.
引用
收藏
页码:777 / 783
页数:7
相关论文
共 50 条
  • [1] IN-VITRO ACTIVITY OF PIPERACILLIN/TAZOBACTAM AGAINST RECENT CLINICAL ISOLATES FROM HOSPITALIZED-PATIENTS IN 10 BELGIAN HOSPITALS
    VERBIST, L
    DHOORE, P
    ACTA CLINICA BELGICA, 1995, 50 (05): : 274 - 281
  • [2] In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates
    M. Cormican
    G. Corbett-Feeney
    S. Kelly
    D. Hughes
    J. Flynn
    R. N. Jones
    Irish Journal of Medical Science, 1998, 167 : 155 - 159
  • [3] In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates
    Cormican, M
    Corbett-Feeney, G
    Kelly, S
    Hughes, D
    Flynn, J
    Jones, RN
    IRISH JOURNAL OF MEDICAL SCIENCE, 1998, 167 (03) : 155 - 159
  • [4] In vitro activity of piperacillin/tazobactam against isolates from patients enrolled in clinical trials
    Kuck, NA
    Jacobus, NV
    Spengler, MD
    Testa, RT
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1996, 7 (01) : 15 - 21
  • [6] Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients
    Casellas, JM
    Tomé, G
    Bantar, C
    Bertolini, P
    Blázquez, N
    Borda, N
    Couto, E
    Cudmani, N
    Guerrera, J
    Juárez, MJ
    López, T
    Littvik, A
    Méndez, E
    Notario, R
    Ponce, G
    Quinteros, M
    Salamone, F
    Sparo, M
    Sutich, E
    Vaylet, S
    Wolff, L
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 47 (03) : 527 - 537
  • [7] COMPARATIVE ACTIVITIES OF PIPERACILLIN AND TAZOBACTAM AGAINST CLINICAL ISOLATES OF LEGIONELLA SPP
    COLLINS, LA
    WENNERSTEN, CB
    FERRARO, MJ
    MOELLERING, RC
    ELIOPOULOS, GM
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (01) : 144 - 146
  • [8] MULTICENTER SURVEY OF THE COMPARATIVE IN-VITRO ACTIVITY OF PIPERACILLIN TAZOBACTAM AGAINST BACTERIA FROM HOSPITALIZED-PATIENTS IN THE BRITISH-ISLES
    CHEN, HY
    BONFIGLIO, G
    ALLEN, M
    PIPER, D
    EDWARDSON, T
    MCVEY, D
    LIVERMORE, DM
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 (02) : 247 - 266
  • [9] INCREASED IN-VITRO ACTIVITY OF CEFTRIAXONE BY ADDITION OF TAZOBACTAM AGAINST CLINICAL ISOLATES OF ANAEROBES
    ALDRIDGE, KE
    MORICE, N
    SCHIRO, DD
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1994, 19 (04) : 227 - 234
  • [10] In-vitro activity of piperacillin and tazobactam combination against clinically significant bacteria
    Obi, CL
    Makandiramba, B
    Robertson, V
    Tswana, SA
    Moyo, SR
    Nziramasanga, P
    EAST AFRICAN MEDICAL JOURNAL, 1998, 75 (03) : 162 - 165